Vensica Medical a pioneering urology therapeutics company, announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its...
form of dry AMD that causes damage to retinal tissue, eventually leading to blindness. In the US alone, approximately 1.5 million people are affected by this condition. Last year, the first treatment for GA was approved by the FDA in the US....
significant and sustained HAE attack rate reductions after initiating ORLADEYO in patients with HAE, regardless of their C1-inhibitor (C1-INH) deficiency status, and new findings from an HAE patient survey confirming patient preference for an oral...
On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB...
the first participant has been dosed in the Randomized Placebo Controlled Double Blind Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy. Type 1 (DM1). DM1 is a devastating rare neuromuscular disorder that causes muscle weakness and...
PET/computed tomography (CT) to detect recurrence of prostate cancer. Evaluation will be across 2 imaging timepoints, Day 1 (day of administration, same-day imaging) and Day 2 (approximately 24 hours post administration, next-day imaging). The...
pulmonary and fibrosis indications, announced the presentation of two abstracts detailing LTI-03's pre-clinical and Phase 1b (NCT05954988) results in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway...
Arabia. Eisai Saudi Arabia is a wholly-owned subsidiary of Eisai’s European regional headquarters, Eisai Europe. In the 1960s, Eisai started business in the Middle East marketing and selling Eisai products through local distribution partners. In...
further positive developments for its novel investigational radioligand therapies. Enrolment of patients in the Phase 1 trial of Lutetium (177Lu) rhPSMA-10.1 Injection was completed in July. Early data from the trial suggests an encouraging safety...
Prendio-BioProcure, a leader in procurement solutions for the life science industry, is excited to launch PrendioPay, an integrated payment platform that evolves the operational reality that most biotech companies face in their business today –...
Hansa Biopharma AB, announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing...
Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker’s biophysical portfolio for...
enabling researchers to make meaningful advances in their fields. Promega invites attendees of SFN 2024 to Booth #1316 to experience live demonstrations of the Glomax® Galaxy, showcasing its potential to transform research. About Promega...
in Tempe, Arizona, BioCare, Inc. has been devoted to delivering specialty and therapeutic biological products since 1982. For more information, visit www.BioCare
to accelerate production of vaccine-relevant proteins for use in clinical trials. This project fully aligns with the 100 Days Mission spearheaded by CEPI. The project extension follows a successful first six months during which LenioBio achieved...
international standards of excellence in training and was awarded following a comprehensive audit under the ANSI/ASTM E2659-18 standard. This validates that ISCT's training programs are built on robust quality management systems, thorough learner...
Treatment of Metastatic Tumors Harboring an Ataxia-Telangiectasia Mutated (ATM) Mutation.” “These encouraging early Phase 1 data build further support for the broad clinical potential of camonsertib,” said Maria Koehler, MD, PhD, Executive Vice...
stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like...
medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors “Today’s landmark approval of our first-in-class treatment for...
diseases announced that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in Hepatology. Previously, Galmed reported results from the...